

# Nucleic sample detection platform

The Vidiera NsD nucleic sample detection platform from Beckman Coulter separates DNA molecules post-amplification by capillary electrophoresis. It can run two 96-well plates, and the second plate can be added while the first plate is running—allowing technicians to add rush samples during the run. The Vidiera NsD significantly reduces the time required to separate nucleic acids for further analysis, running batches of eight samples in as little as 30 minutes. Furthermore, technicians can rapidly change onboard supplies such as separation gels and capillary arrays, which reduces set up time.

http://www.beckmancoulter.com/



#### Columns and accessories

Polysciences offers pre-measured sterile nylon wool fiber (NWF) columns, ideal for separating T-cell and B-cell lymphocytes. B cells selectively adhere to NWF whereas T-cells do not, with recovery rates up to 90%. Columns are packaged in ready-to-use 10-cc disposable syringes, packed to the 5-cc line with 0.5 g of NWF that has been pulled into thin, fine strands. The wool fiber is also available in bulk quantities of 10 g and 50 g, enabling researchers to pack columns of any size.

http://www.polysciences.com/

# High-throughput screening



software is easily integrated into Wyatt's 21 CFR 11-compliant ASTRA platform. http://www.wyatt.com/



### Dynamic light scattering

Wyatt Technology's DynaPro Dynamic Light Scattering (DLS) system for high-throughput screening is a powerful yet easy-to-use tool for characterizing unfractionated samples for applications such as protein crystallography and aggregation studies. Features include a control module with the ability to collect and analyze data; and a read module, which comes as either a temperature-controlled scintillation vial reader for single measurements, or a fully automated plate reader with the capability to make measurements on 96- or 384-well plates. The DynaPro's

## Screening service

Invitrogen offers pharma and biotech partners a fee-for service and subscription service for rapid and selective compound profiling against a comprehensive set of therapeutically relevant protein kinase targets. Assays are performed using proteins and assays developed at Invitrogen. A portfolio of 142 distinct kinases for profiling small molecule inhibitors is available, with a 2-week turnaround.

http://www.invitrogen.com/drugdiscovery/